Leon-nanodrugs GmbH (LEON), a pharmatech firm specializing within the improvement of nanoencapsulation programs for genetic materials and different lively substances, introduced in the present day the closing of a Collection D financing spherical. New lead investor LBBW Enterprise Capital closed the spherical along with new buyers and present shareholders like Albany Non-public Fairness Holdings Pty Ltd., CD-Enterprise GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Companions, TVM Life Science Innovation I L.P., and others.
“I’m more than happy that we’ve got accomplished this financing within the deliberate quantity. The brand new funds will probably be used to enhance the product portfolio. Our portfolio of main tools is designed to serve the Cell & Gene Remedy trade, enabling extremely financial GMP manufacturing of small and individualized batches of nanoencapsulated Cell & Gene Therapies. Along with the financing, this places us in a superb place to pick the very best strategic companion to carry these merchandise to the market”, commented Christian Nafe, Managing Director & CFO of LEON.
LEON’s strongly differentiated programs provide important USP’s filling present trade gaps:
- NANOscreen: bench-top system for simplified formulation screening
- NANOlab®: bench-top system for quick and environment friendly course of improvement
- NANOme® : aseptic manufacturing system for top throughput small- and individualized scale
- GMP manufacturing requiring no cleansing and sterilization as a result of a single use element
- NANOus® : massive scale manufacturing unit for business, sterile GMP batches.
The underlying FR-JET® reactor expertise is ready for future versatility of service materials, and is optimized for minimal batch losses, and no scaling out. It’s included in all NANO-systems permitting to seamlessly scale up from course of improvement to business manufacturing.
Dr. Frank Mühlenbeck, representing lead investor LBBW Enterprise Capital, will be part of LEON’s Supervisory Board. He said: “LEON’s merchandise permit the environment friendly improvement and manufacturing of latest, upcoming modalities within the biopharma trade together with LNP’s with a particular concentrate on decentralized patient-specific therapies. Along with this bench-to-bedside strategy, LEON’s merchandise additionally empower CDMOs providing centralized manufacturing of such therapies. We utterly perceive the trade want for next-generation manufacturing options and are glad to assist LEON of their effort to advance their merchandise to commercialization.”
Dr. Hubert Birner, Managing Accomplice at TVM Life Science Administration and Chairman of LEON’s Supervisory Board said: “As a long-standing investor in LEON, we welcome the funding of LBBW VC, because it comes at a pivotal time for LEON to facilitate use of our lead merchandise available in the market. Whereas drugs of in the present day embraces increasingly more Cell & Gene Therapies, a sensible answer for cost-efficient, quick and but dependable and protected manufacturing continues to be required.”
